Progesterone Microspheres Pharmacokinetic - Pharmacodynamic (PK-PD) Study
- Registration Number
- NCT01176175
- Lead Sponsor
- Productos Científicos S. A. de C. V.
- Brief Summary
Phase: I pharmacokinetic - pharmacodynamic (PK-PD) study. Main objective: To establish the minimum effective dose of progesterone microspheres suspension, which administered by weekly intramuscular injection, will be able to induce transformation from a proliferative endometrium to a secretory endometrium.
Study design: Randomized, controlled, open-label, parallel, dose-response clinical trial.
Sites: 1 Subjects: 48 postmenopausal women.
- Detailed Description
Sites: 1 Phase: 1 Main objective:To establish the minimum effective dose of progesterone microspheres suspension, which administered by weekly intramuscular injection, will be able to induce transformation from a proliferative endometrium to a secretory endometrium.
Secondary objectives:
* To determine and compare the steady-state pharmacokinetic profile of investigational products.
* To evaluate safety profile of investigational products in the study subjects.
* To evaluate local tolerability of investigational products in the study subjects.
Study design:Randomized, controlled, open-label, parallel, dose-response clinical trial.
Investigational products:
* Progesterone microspheres intramuscular injectable suspension 50 mg
* Progesterone microspheres intramuscular injectable suspension 100 mg
* Progesterone microspheres intramuscular injectable suspension 200 mg
* Progesterone microspheres intramuscular injectable suspension 300 mg Study subjects: 48 healthy postmenopausal women, 45 - 60 years. Brief description: After written informed consent, 48 eligible women will receive pretreatment with oral estradiol valerate, then, 14 days later, those with adequate endometrial thickness evaluated through ultrasound will be randomized to study treatments (one IM injection each 7 days, for a total of 7 doses). 10 days after the first progesterone dose, an endometrial biopsy will be obtained. Blood samples will be obtained for pharmacokinetic study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 48
- Female
- 45 to 60 years old
- Able to read and write
- Postmenopausal
- Body Mass Index equal or below 34.99 kg/m2
- Healthy
- Normal uterus
- Time availability
- Hypersensitivity to progesterone or related compounds
- Hypersensitivity to estrogens
- Hysterectomy
- History or present hormone-dependent tumor
- History or present uterine cervix dysplasia
- Abnormal and clinically-significant laboratory test results
- Family history of breast cancer
- History of thromboembolic disease
- Non-controlled hypertension
- History of stroke
- History of cardiac valve surgery
- Renal failure
- Hepatic failure
- Non-controlled diabetes
- Severe gastrointestinal disease
- History of serious neurologic disease
- Reduced mobility
- Anemia
- Previous or concomitant hormonal therapy
- Previous or concomitant therapy with inhibitors or inductors of cytochrome
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 50 mg Progesterone Progesterone microspheres injectable suspension 50 mg 300 mg Progesterone Progesterone microspheres injectable suspension 300 mg 200 mg Progesterone Progesterone microspheres injectable suspension 200 mg 100 mg Progesterone Progesterone microspheres injectable suspension 100 mg
- Primary Outcome Measures
Name Time Method Endometrial dating through histopathologic criteria. 10 days Endometrial dating according Noyes criteria as a measure of efficacy. At the moment of the biopsy, study subjects would have received 25 days of estradiol valerate pretreatment and 10 days of progesterone (investigational product); thus simulating the 25th day of a menstrual cycle. Efficacy will be measured as number of biopsies that have histological date according to cronological date.
- Secondary Outcome Measures
Name Time Method Pharmacokinetics 0 -60 days. Progesterone plasmatic concentrations and pharmacokinetic parameters.
Adverse events 0 - 65 days Number of Participants with Adverse Events as a Measure of Safety and Tolerability Pain Scores on a Visual Analog Scale
Trial Locations
- Locations (1)
Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)
🇲🇽Pachuca, Hidalgo, Mexico